Login to Your Account

Prosensa Treats First Patient in Phase III Trial of DMD Drug

By Nuala Moran

Thursday, January 27, 2011
LONDON – Prosensa NV announced that the first patient has started treatment in the Phase III trial of its lead antisense product for treating the progressive, inherited muscle-wasting disease Duchenne's muscular dystrophy (DMD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription